Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of anticoagulant effect of dabigatran and rivaroxaban
2012-002263-96Phase 4Active
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dabigatran and rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Thrombin generation, Variation in anticoagulant effect between patients and 4 more. Started Jun 2012; status: active.
02
Drugs
dabigatranrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2012-002263-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002263-96.